Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859620 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4038101 | 1.00 | CYP3A4 (0.63) | CYP3A4CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL5901455 | 0.99 | CYP3A4 (0.62) | CYP3A4CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL5901203 | 0.99 | CYP3A4 (0.62) | CYP3A4CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL5965237 | 0.99 | CYP3A4 (0.62) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4040106 | 0.92 | CYP3A4 (0.54) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL5901357 | 0.90 | CYP3A4 (0.52) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL5744918 | 0.88 | CYP3A4 (0.64) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL5415553 | 0.88 | CYP3A4 (0.59) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4036205 | 0.88 | CYP3A4 (0.50) | CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-7452889-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2008-02-07 | — | — | US | disclosed |
| US-7262198-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070191390-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ZABLOCKI JEFF | 2007-08-16 | — | — | US | disclosed |
| US-7208496-B2 | Treatment of cardiovascular diseases and diabetes; {4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-(trifluoromethyl)phenyl]thiocarboxamide for example; fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1723129-A1 | 1-AKAN-2-OL SUBSTITUTED PIPERAZINE AND PIPERIDINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060229317-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2006-10-12 | — | — | US | disclosed |
| US-7115610-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050197346-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6930111-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2005-08-16 | — | — | US | disclosed |
| WO-2005061470-A1 | 1-AKAN-2-OL SUBSTITUTED PIPERAZINE AND PIPERIDINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1406898-B1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20050049254-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2005-03-03 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-1406898-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030181352-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003008411-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049254-A1 | Substituted heterocyclic compounds | KCNH1, KCNJ2, SCN5A | CYP3A4 1273/4885CYP1A2 1003/4885CYP2C9 1115/4885 |
| US-20030181352-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | CYP3A4 729/4885CYP1A2 849/4885CYP2C9 698/4885 |
| US-20060229317-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CYP3A4 608/4885CYP1A2 530/4885CYP2C9 357/4885 |
| US-20070191390-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | CYP3A4 598/4885CYP1A2 782/4885CYP2C9 414/4885 |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | CYP3A4 608/4885CYP1A2 530/4885CYP2C9 357/4885 |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | CYP3A4 608/4885CYP1A2 530/4885CYP2C9 357/4885 |
| US-20050197346-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CYP3A4 608/4885CYP1A2 530/4885CYP2C9 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.